OnBioVC

Phosphate Therapeutics, Ltd.: Series A $13.8M

arubenstein — Mon, 21 May 2012 05:14:05 +0000

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

S.E.A. Medical Systems, Inc.: Series B $3M

arubenstein — Mon, 21 May 2012 05:08:28 +0000

S.E.A. Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

Mevion Medical Systems, Inc.: Series G $45M

arubenstein — Mon, 21 May 2012 05:06:16 +0000

Mevion Medical Systems (Littleton, MA) a commercial-stage medical device company focused on proton beam radiotherapy device for cancer, closed a $45M Series G financing. Participants include ProQuest Investment, Caxton Heath Life Sciences, Venrock and CHL Medical Partners.

CN Creative, Ltd: Series A $3.1M

arubenstein — Mon, 21 May 2012 05:01:14 +0000

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $3.1M Series A financing. Participants include Advent Life Sciences.

ImmuneXcite, Inc.: Series A $2.4M

arubenstein — Mon, 21 May 2012 04:22:13 +0000

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Heat Biologics, Inc.: Series A $2.8M

arubenstein — Mon, 21 May 2012 04:16:01 +0000

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

Pulse Therapeutics, Inc.: Series B $3.1M

arubenstein — Mon, 21 May 2012 04:11:19 +0000

Pulse Therapeutics (St. Louis, MO) a development-stage medical device company focused on vascular drug delivery device for blood clots in stroke patients , closed a $3.1M Series B financing. Participants include BioGenerator.

3-V Biosciences, Inc.: Series C $20M

arubenstein — Mon, 21 May 2012 04:08:36 +0000

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

CytoPherx, Inc.: Series C $34M

arubenstein — Mon, 21 May 2012 04:05:23 +0000

CytoPherx (Ann Arbor, MI) a clinical-stage medical device company focused on dialysis filters to sequester and deactivate leukocytes in the patient’s blood system for acute renal failure, closed a $34M Series C financing. Participants include Early Stage Partners, Onset Ventures and Capital Midwest Fund.

CrystalGenomics, Inc.: Series A $2.6M

arubenstein — Mon, 21 May 2012 03:54:37 +0000

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford Bioscience Partners.

MedGenesis Therapeutix, Inc.: Series C $5M

arubenstein — Mon, 21 May 2012 03:29:26 +0000

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

Natura, Inc.: Series D $20M

arubenstein — Mon, 21 May 2012 03:27:14 +0000

Natura, f/k/a Gene Security Network (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and diseases such as Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

SEA Medical Systems, Inc.: Series B $3M

arubenstein — Tue, 24 Apr 2012 07:00:58 +0000

SEA Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.